NovaBridge Biosciences
NBP
$2.06
-$0.04-1.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 196.61% | 52.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 710.99% | 26.36% | |||
| Operating Income | -710.99% | -26.36% | |||
| Income Before Tax | -967.05% | -24.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -967.05% | -24.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -967.05% | -24.06% | |||
| EBIT | -710.99% | -26.36% | |||
| EBITDA | -712.36% | -26.44% | |||
| EPS Basic | -862.31% | 2.77% | |||
| Normalized Basic EPS | -840.59% | 2.85% | |||
| EPS Diluted | -862.31% | 2.77% | |||
| Normalized Diluted EPS | -840.59% | 2.85% | |||
| Average Basic Shares Outstanding | 10.88% | 27.55% | |||
| Average Diluted Shares Outstanding | 10.88% | 27.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||